Atheronova Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2009
2010
2011
2012
2013
Cash & Short Term Investments
7.00
177.80
616.10
2,744.00
266.20
Total Accounts Receivable
-
14.00
-
-
-
Other Current Assets
-
-
12.90
17.60
22.40
Total Current Assets
7.00
191.80
629.00
2,761.70
288.60
Net Property, Plant & Equipment
-
5.50
4.00
8.50
7.40
Other Assets
-
-
-
23.80
12.80
Total Assets
7.00
197.40
633.00
2,794.00
308.80
ST Debt & Current Portion LT Debt
856.50
-
-
-
390.10
Accounts Payable
15.70
157.70
170.40
603.60
811.40
Other Current Liabilities
13.70
13,720.50
6,250.70
37.00
76.50
Total Current Liabilities
886.00
13,878.20
6,421.20
640.60
1,278.00
Long-Term Debt
-
228.30
395.70
360.80
363.10
Other Liabilities
-
-
-
-
1,170.70
Total Liabilities
886.00
14,106.50
6,816.80
1,001.40
2,811.80
Common Equity (Total)
878.90
13,909.10
6,183.90
1,792.50
2,503.00
Total Shareholders' Equity
878.90
13,909.10
6,183.90
1,792.50
2,503.00
Total Equity
878.90
13,909.10
6,183.90
1,792.50
2,503.00
Liabilities & Shareholders' Equity
7.00
197.40
633.00
2,794.00
308.80

About Atheronova

View Profile
Address
2301 Dupont Drive
Irvine California 92612
United States
Employees -
Website -
Updated 07/08/2019
AtheroNova, Inc. is a biotechnology company. The company engages in the research and development, marketing, and sale of pharmaceutical preparations and pharmaceutical intellectual property. It develops intellectual property that uses certain pharmacological compounds for the treatment of atherosclerosis, which is the primary cause of various cardiovascular diseases.